782
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The relative weak way and the absolute strong way to communicate risk information

ORCID Icon, & ORCID Icon

References

  • Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of alpha and delta variant prevalence.medRxiv. 2021. DOI:10.1101/2021.08.06.21261707
  • Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat-which of these should we use? Value Health. 2002;5(5):431–436.
  • Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016;7(1):51–53.
  • Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100–107.
  • von Elm E, Altman DG, Egger M, STROBE Initiative, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLOS Med. 2007;4(10):e296.
  • Shamseer L, Hopewell S, Altman DG, et al. Update on the endorsement of CONSORT by high impact factor journals: a survey of journal “‘Instructions to Authors’ in 2014”. Trials. 2016;17(1):301.
  • Schwartz LM, Woloshin S, Dvorin EL, et al. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ. 2006;333(7581):1248.
  • Jaeschke R, Guyatt G, Shannon H, et al. Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association. CMAJ. 1995;152(3):351–357.
  • King NB, Harper S, Young ME. Use of relative and absolute effect measures in reporting health inequalities: structured review. BMJ. 2012;345:e5774.
  • Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, et al. Systematic reviews experience major limitations in reporting absolute effects. J Clin Epidemiol. 2016;72:16–26.
  • Vinkers CH, Lamberink HJ, Tijdink JK, et al. The methodological quality of 176,620 randomized controlled trials published between 1966 and 2018 reveals a positive trend but also an urgent need for improvement. PLoS Biol. 2021;19(4):e3001162.
  • Saleem MD, Kesty C, Feldman SR. Relative versus absolute risk of comorbidities in patients with psoriasis. J Am Acad Dermatol. 2017;76(3):531–537.
  • Tjahjono LA, Cline A, Huang WW, et al. Rosacea: relative risk versus absolute risk of malignant comorbidities. J Am Acad Dermatol. 2019;81(2):623–624.
  • Egeberg A, Hansen PR, Gislason GH, et al. Patients with rosacea have increased risk of dementia. Ann Neurol. 2016;79(6):921–928.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.